Maharashtra FDA Flags Up To 2841 Percent Markup On Hospital Consumables Urging NPPA Price Caps

A regulatory survey in Maharashtra has laid bare excessive profit margins in private healthcare billing, triggering calls for central intervention on hospital consumables. Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has formally written to the Department of Pharmaceuticals (DoP) and the National Pharmaceutical Pricing Authority (NPPA), urging the Centre to establish clear guidelines on permissible trade margins and bring essential medical consumables under strict statutory price controls.

The action follows an investigation by the Maharashtra State Price Monitoring Resource Unit (MSPMRU), which audited procurement rates and maximum retail prices (MRPs) across more than 20 hospitals in Mumbai Metropolitan Region, Pune, and Chhatrapati Sambhajinagar.

Key Findings From The FDA Market Survey:

• Intravenous (IV) Infusion Sets: Purchased by hospitals at a trade procurement price of ₹11.05, these items carried a printed MRP of ₹325, translating to an exorbitant markup of 2,841%.
• Disposable Syringes: A standard 10 ml syringe procured by healthcare facilities at ₹6.75 was billed to patients at an MRP of ₹57.20, representing an inflation of nearly 747%.
• Catheters: Acquired at trade prices around ₹29.41, catheters carried declared MRPs of ₹310, marking a markup of over 950%.
• Nebuliser Kits And Oxygen Masks: Items procured between ₹40 and ₹45 reached consumer invoices at ₹650 to ₹715, posting markups ranging from 1,300% to 1,600%.

A Captive Consumer Dilemma

Flagging the issue publicly and in formal correspondence with central authorities, Mundhe emphasised that consumable pricing in an inpatient setting constitutes a critical public health issue rather than an ordinary market dynamic.

Unlike over-the-counter pharmaceuticals where consumers can choose generic alternatives or negotiate discounts, hospitalised patients have zero bargaining power. Trade channels often allow manufacturers to print artificially inflated MRPs at the behest of institutional buyers, creating massive spreads that hospitals monetize directly through in-house pharmacies. Mundhe noted that the initial trade procurement price already factors in manufacturer production, research, overheads, and profits, leaving the final margin escalation unjustified.

Push For DPCO Expansion

Under the existing framework of the Drugs (Prices Control) Order (DPCO), 2013, the NPPA sets ceiling prices primarily for scheduled formulations and selected high-profile medical devices, such as coronary stents and knee implants. For non-scheduled devices, manufacturers are merely restricted to an annual price hike cap of 10% under Paragraph 20, leaving initial MRP declarations largely unregulated.

The Maharashtra FDA has recommended that the central government:

• Bring commonly used surgical consumables and medical devices under Section 4 of the DPCO, 2013, empowering the NPPA to fix direct ceiling prices.
• Implement a Trade Margin Rationalisation (TMR) mechanism across hospital supplies, similar to caps enforced during the pandemic on oxygen concentrators.
• Mandate transparency audits on hospital supply chains to restrict the gap between manufacturer issue price and final patient billing.

Implications For Healthcare Providers And Investors

For domestic hospital operators, medical consumables and in-house pharmacy sales represent a key contributor to average revenue per occupied bed (ARPOB) and operating EBITDA margins. If the NPPA initiates a structured trade-margin rationalisation exercise across syringes, IV sets, and catheter lines, private hospital chains may face margin compression unless charges are transparently restructured into room rates and procedural fees.

Simultaneously, medical technology manufacturers and domestic suppliers represented by industry associations are advocating for balanced reforms. While domestic device lobbies like AiMeD have historically supported rationalised margins to curb predatory institutional procurement, hospital administrators caution that sudden blanket caps could dent capital expenditure allocations for healthcare infrastructure and patient safety technology.

Tags: Healthcare NPPA Department of Pharmaceuticals Hospitals Medical Devices